Durable Response to Programmed Death 1-Directed Antibodies in a Hypermutated Triple-Negative Breast Cancer: A Case Report

Durable Response to Programmed Death 1-Directed Antibodies in a Hypermutated Triple-Negative Breast Cancer: A Case Report

Introduction: The advent of immune checkpoint inhibitors marks significant progress in the evolution of cancer treatment. Recent clinical trials have demonstrated the success of immune-oncologic (IO) agents like pembrolizumab (Keytruda™) in combination with chemotherapy against triple-negative breas...

Full description

Bibliographic Details
Main Authors: Emilie Platteter, Gerburg Wulf
Format: Article
Language:English
Published: Karger Publishers 2024-03-01
Series:Case Reports in Oncology
Subjects:
triple-negative breast cancer
programmed death 1
microsatellite instability-high
immune-oncology
hypermutated tumor
next-generation sequencing
case report
Online Access:https://beta.karger.com/Article/FullText/535743

Internet

https://beta.karger.com/Article/FullText/535743

Similar Items